Neoadjuvant TKI therapy in non-metastatic GIST patients can reduce surgical complexity, with CE-CT imaging predicting benefits in 22 of 39 patients. Significant tumor volume reduction was observed ...

Tyrosine kinase inhibitors such as imatinib play a crucial role in treating GISTs by targeting specific proteins involved in tumor growth. This tyrosine kinase inhibitor (TKI) blocks the activity ...

KIT-directed tyrosine kinase inhibitors (TKIs) are the key treatment for advanced GISTs, but TKI resistance because of secondary mutations often emerges. Novel approaches to overcome TKI resistance, ...

Patients had to have had measurable disease and no prior history of taking a TKI for metastatic disease. Regarding exclusion criteria, patients who had progression of GIST while on adjuvant therapy ...

comprises high-risk intestinal GISTs with high infiltration of immune cells, especially CD8 + T cells, suggesting that these tumors may benefit from a combination of TKI therapy and immunotherapy.

A type of targeted cancer drug used for GIST is called a tyrosine kinase inhibitor (TKI). Tyrosine kinase inhibitors (TKIs) block chemical messengers (enzymes) called tyrosine kinases. Tyrosine ...

Acquisition includes IDRX-42, a highly selective KIT tyrosine kinase inhibitor (TKI) designed to treat gastrointestinal stromal tumours (GIST) IDRX-42 offers potential to address all key KIT ...

The tyrosine kinase inhibitor (TKI) is designed to be a first- and second-line therapy for gastrointestinal stromal tumors (GIST) by hitting all key KIT mutations, something that gives the asset ...

3rd and 4th line GIST respectively, however disease progression occurs within a few months. This is the problem Theseus is approaching with its TKI-experienced team and pan-variant TKIs.

IDRX-42 is a selective tyrosine kinase inhibitor (TKI) designed to treat gastrointestinal stromal tumours (GIST) by targeting ...

The acquisition includes lead molecule, IDRX-42, a highly selective KIT TKI being developed as a first- and second-line therapy for the treatment of GIST. “IDRX-42 complements our growing ...

The acquisition includes lead molecule, IDRX-42, a highly selective KIT TKI being developed as a first- and second-line therapy for the treatment of GIST. GIST typically presents in the GI tract ...